Naiara Alvarez, MD
Rheumatology · Harlingen, TXNPI 1578873857
Payments from drug & device makers
Across 561 payments — averaging $357.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$68K
- AbbVie$60K
- Janssen Research & Development, LLC$36K
- Pfizer$25K
- Sobi, Inc$3K
- Amgen$3K
- plus $6K from 22 others
What the payments were for
- Consulting fees$4,09826%
- Grants$2401%
- Food & beverage$11,28970%
- Education$3982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $67,939 |
| AbbVie | 111 | $59,739 |
| Janssen Research & Development, LLC | 5 | $36,003 |
| Pfizer | 40 | $24,638 |
| Sobi, Inc | 3 | $3,398 |
| Amgen(2 entities) | 131 | $2,723 |
| Johnson & Johnson(2 entities) | 68 | $2,142 |
| Novartis | 32 | $619 |
| Aurinia Pharma U.S., Inc. | 36 | $609 |
| Lilly USA, LLC | 12 | $355 |
| Janssen Scientific Affairs, LLC | 3 | $346 |
| GSK | 18 | $324 |
| Sanofi | 11 | $312 |
| ANI Pharmaceuticals, Inc. | 10 | $276 |
| UCB, Inc. | 9 | $237 |
| Radius Health, Inc. | 6 | $201 |
| E.r. Squibb & Sons, L.L.C. | 10 | $154 |
| Genentech USA, Inc. | 6 | $135 |
| Medtronic | 1 | $118 |
| Sanofi-aventis U.S. LLC | 2 | $106 |
| Actelion Pharmaceuticals US, Inc. | 1 | $98 |
| Boehringer Ingelheim | 2 | $72 |
| Octapharma USA, Inc. | 3 | $60 |
| Organon | 2 | $48 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Si-bone, Inc. | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$200,715 in reported general payments places this provider in the 85th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 59 | $4,187,945 |
| KrystexxaPegloticase | 44 | $2,410,760 |
| Enbrel MiniEtanercept | 290 | $2,118,298 |
| RinvoqUpadacitinib | 270 | $1,693,847 |
| Humira(Cf) PenAdalimumab | 201 | $1,650,933 |
| Enbrel SureclickEtanercept | 196 | $1,542,146 |
| VyvgartEfgartigimod Alfa-Fcab | 18 | $1,279,605 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 128 | $941,202 |
| Xeljanz XrTofacitinib Citrate | 153 | $876,880 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 92 | $811,544 |
| ActemraTocilizumab | 288 | $771,514 |
| SolirisEculizumab | 13 | $757,795 |
| RemicadeInfliximab | 120 | $741,180 |
| OrenciaAbatacept/Maltose | 127 | $541,222 |
| TremfyaGuselkumab | 35 | $455,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris, Soliris, Saphnelo | $67,939 | $5,105,961106 claims |
| AmgenKrystexxa, Prolia, Otezla, Enbrel, Avsola | $2,723 | $3,347,167385 claims |
| AbbVieRinvoq, Humira(Cf) | $59,739 | $1,841,553292 claims |
| Johnson & JohnsonRemicade, Tremfya, Simponi Aria | $2,142 | $1,550,783210 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $154 | $598,444138 claims |
| PfizerInflectra, Ruxience, Xeljanz | $24,638 | $488,28686 claims |
| UCB, Inc.Cimzia (2 Pack) | $237 | $440,15874 claims |
| Radius Health, Inc.Tymlos | $201 | $216,55273 claims |
| GSKBenlysta | $324 | $92,35735 claims |
| NovartisCosentyx (2 Syringes) | $619 | $89,05812 claims |
| OrganonRenflexis | $48 | $80,87611 claims |
| SanofiKevzara | $312 | $55,29113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Harlingen
- Paul PickrellAustin$40.9M
- Atul SinghalMesquite$13.9M
- Shaikh AliTomball$9.8M
- Jitendra VasandaniLubbock$6.4M
- Dhiman BasuColleyville$6.2M
- Tamar BrionezThe Woodlands$5.2M
- Philip WallerHouston$4.9M
- John CushDallas$3.9M
- Sabeen NajamBaytown$3.6M
- Sanjay ChabraEl Paso$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.